Full Description

Analgesic compounds have very wide applications in human and animal health, one of which is pain control.  In mammals, cytochrome P450 epoxygnases metabolize arachidonic acid and yields epoxy-eicosatrienoic acids (EETs).  The EETs are thereafter metabolized by soluble epoxide hydrolase (sEH).  EETs and inhibitors of sEH have previously been shown to be effective in reducing pain when administered systemically or topically.

Researchers at the University of California, Davis have discovered that the analgesic effect of EETs and sEH inhibitors requires the presence of increased intracellular levels of cyclic adenosine monophosphate (cAMP).  Thus, the co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors with agents that increase the intracellular levels of cAMP will be useful in increasing analgesia.

Applications

• The combined administration of EETs, sEH inhibitors, or EETs and sEH inhibitors, with agents that increase intracellular cAMP levels can be used for the treatment and management of acute and chronic pain.
• The co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors with agents that increase the intracellular levels of cAMP may be used to reduce the number or delay the onset of seizures.
• EETs and sEH inhibitors can be used to alleviate symptoms of diseases that are associated with naturally occurring increased levels of intracellular cAMP. For example, increased levels of intracellular cAMP are known to occur during withdrawal from opioids. EETs, sEH inhibitors, or both can be administered during withdrawal to alleviate withdrawal symptoms.

Features/Benefits

• The co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors with agents that increase the intracellular levels of cAMP can be used to manage and treat pain.
• The co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors can be administered to patients with a naturally occurring increased cAMP level to alleviate pain.
• The co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors with agents that increase the intracellular levels of cAMP can be used as a sedative, and can also facilitate recovery from anesthesia.
• The co-administration of EETs, sEH inhibitors, or EETs and sEH inhibitors with agents that increase the intracellular levels of cAMP may be used to delay the onset of seizures.

PATENT STATUS

• Patent Pending

INVENTORS

• Hammock, Bruce D.
• Inceoglu, Bora
• Jinks, Steven L.

Other Information

Contact

Barbara A. Boczar/ baboczar@ucdavis.edu / tel: 530-754-8606. Please reference Tech ID #18952.

Request Additional Information

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

• Inhibitors of Soluble Epoxide Hydrolase to Inhibit or Prevent Niacin-Induced Flushing
• Improved Dioxin Detection and Measurement
• Recombinant Neurotoxin: A More Effective Insecticide
• Immunoassay for Polyunsaturated Fatty Acid Metabolites
• Enzyme Reporter Molecule
• Immunoassay on a Compact Disc (CD): Support With Interactive Data Storage
• Molecular Receptors for Epoxyeicosatrienoic Acids (EETs)
• Transgenic Plants with Increased Tolerance for Stress and Pathogens
• Substituted Aminopyridines as Fluorescent Reporters or Substrates for Amidases, Aminopeptides, and Other Enzymes Including FAAH
• Development of Non-Competitive Immunoassays for Small Analytes
• Inhibition of Epoxide Hydrolase Phosphatase Activity
• Antibodies: Urea Herbicide Pabs
• Antibodies: Triazine Herbicide Pabs
• Antibodies: Bacillus Delta Endotoxin PAbs
• Antibodies: Bromacil Herbicide PAbs
• Soluble Epoxide Hydrolase Inhibitors as Novel Pain Reducing Agents
• Soluble Epoxide Hydrolase Inhibitors as Novel Pain Reducing Agents
• Potent Inhibitors of Soluble Epoxide Hydrolase (sEH)
• Prevention of Cardiac Myopathy and Failure by Soluble Epoxide Hydrolase (sEH) Inhibitors
• Inhibitors of Soluble Epoxide Hydrolase as Intraocular Hypotensive Agents
• A Method for Assessing the Presence and Degree of Inflammation in Inflammatory Diseases Involving Kidney Dysfunction